CN110227157A - Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method - Google Patents
Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method Download PDFInfo
- Publication number
- CN110227157A CN110227157A CN201910541710.8A CN201910541710A CN110227157A CN 110227157 A CN110227157 A CN 110227157A CN 201910541710 A CN201910541710 A CN 201910541710A CN 110227157 A CN110227157 A CN 110227157A
- Authority
- CN
- China
- Prior art keywords
- dox
- nano
- fzif
- silicon nano
- gadolinium silicon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AABGKKDTOXGNDF-UHFFFAOYSA-N [Si].[Gd] Chemical compound [Si].[Gd] AABGKKDTOXGNDF-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 88
- 239000002184 metal Substances 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 75
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 64
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 50
- 238000001338 self-assembly Methods 0.000 title claims description 56
- 238000003745 diagnosis Methods 0.000 claims abstract description 69
- 230000010354 integration Effects 0.000 claims abstract description 67
- 238000002156 mixing Methods 0.000 claims abstract description 49
- 239000002105 nanoparticle Substances 0.000 claims abstract description 48
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 25
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 238000012986 modification Methods 0.000 claims abstract description 12
- 230000004048 modification Effects 0.000 claims abstract description 12
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- -1 dimethylaminoethyl Chemical group 0.000 claims abstract description 9
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 4
- 239000013110 organic ligand Substances 0.000 claims abstract description 4
- 239000004698 Polyethylene Substances 0.000 claims abstract description 3
- 229920000573 polyethylene Polymers 0.000 claims abstract description 3
- 230000004043 responsiveness Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 38
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 38
- 239000008367 deionised water Substances 0.000 claims description 26
- 229910021641 deionized water Inorganic materials 0.000 claims description 26
- 229910001868 water Inorganic materials 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 7
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 7
- 229960003330 pentetic acid Drugs 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 229910003317 GdCl3 Inorganic materials 0.000 claims description 6
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 238000005034 decoration Methods 0.000 claims 1
- 238000002242 deionisation method Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 abstract description 10
- 239000011724 folic acid Substances 0.000 abstract description 5
- 230000002902 bimodal effect Effects 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000013267 controlled drug release Methods 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 description 46
- 238000012512 characterization method Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000013154 zeolitic imidazolate framework-8 Substances 0.000 description 6
- MFLKDEMTKSVIBK-UHFFFAOYSA-N zinc;2-methylimidazol-3-ide Chemical compound [Zn+2].CC1=NC=C[N-]1.CC1=NC=C[N-]1 MFLKDEMTKSVIBK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940064302 folacin Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 239000012621 metal-organic framework Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000013105 nano metal-organic framework Substances 0.000 description 1
- 239000013289 nano-metal-organic framework Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000013384 organic framework Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
One kind mixing gadolinium silicon nano/Ce6 photosensitizer self-assembling multifunctional diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA) preparation method, using 2-methylimidazole as organic ligand and Zn2+For metal ion, gadolinium silicon (Si-Gd) nanoparticle will be mixed and the multi-functional diagnosis and treatment integration metal organic frame nanoparticle of reaction system one kettle way rapid synthesis is added in Ce6 photosensitizer, surface modification pH responsiveness PDMAEMA (polymethylacrylic acid dimethylaminoethyl) linear polymer further modifies MaL-PEG-FA (polyethylene glycol-folic acid) realization to the targeting of MCF-7 tumour for realizing the controlled drug release under the slightly sour environment of tumour.FZIF-8/DOX-PD-FA nanoparticle prepared by the present invention can realize the treatment of chemical light Dynamic Synthesis to MCF-7 tumour under fluorescence/magnetic resonance bimodal imaging guidance.
Description
Technical field
The invention belongs to the preparation field of nano material, especially one kind to mix gadolinium silicon nano/photosensitizer Ce6 self assembly
Multi-functional diagnosis and treatment integration metal organic frame nano material preparation method.
Background technique
Currently, nano metal organic framework materials (MOFs) are as the medicament nano carrier with high drug carrying capacity by pass
Note, this is primarily due to MOFs and has the characteristics of biggish pore volume, big specific surface area and aperture can easily be accommodated.Zeolite imidazole
The one kind of framework material (ZIF-8) as MOFs, it has good thermal stability.Meanwhile it is nontoxic and have good life
Object compatibility, and can degrade in acid condition, so ZIF-8 is a kind of good pharmaceutical carrier.Nowadays, to conduct
The ZIF-8 nano materials research development of pharmaceutical carrier is a lot of, but the deficiency as existing for the nano material itself, cannot achieve
Multi-functional diagnosis and treatment integration to target tumor, therefore largely limit its development.Referring to: H.Y.Zhang,
W.Jiang,R.L.Liu,J.Zhang,D.Zhang,Z.H.Li,Y.X.Luan,ACS Appl.Mater.Interfaces,
2017,9,19687-19697；H.Q.Zheng,Y.N.Zhang,L.F.Liu,W.Wan,P.Guo,A.M.Nystrom,
X.D.Zou,J.Am.Chem.Soc.,2016,138,962-968；L.Y.Chen,Y.Peng,H.Wang,Z.Z.Gu,
The silicon nano (Si-GdNPs) that C.Y.Duan, Chem.Commun., 2014,50,8651-8654. mix gadolinium not only has excellent
Good optical property, nontoxic and good biocompatibility can also realize fluorescence and the imaging of magnetic resonance bimodal.Referring to: H.L.Ye,
S.J.Cai,S.Li,X.W.He,W.Y.Li,Anal.Chem.,2016,88,11631-11638；Y.K.Dou,Y.Chen,
X.W.He,W.Y.Li,Y.H.Li,Y.K.Zhang,Anal.Chem.,2017,89,11286-11292；S.Li,F.Wang,
X.W.He, W.Y.Li, Y.K.Zhang, J.Mater.Chem.B, 2018,6,3358-3365. chlorin e 6 (Ce6) photosensitizer
Singlet oxygen can be generated by near infrared light, optical dynamic therapy may be implemented to tumour.L.H.Wu,X.J.Cai,
H.F.Zhu,J.H.Li,D.X.Shi,D.F.Su,D.Yue,Z.W.Gu,Adv.Funct.Mater.,2018,28,1804324；
W.L.Wang,L.Lin,X.J.Ma,B.Wang,S.R.Liu,X.X.Yan,S.R.Li,H.Y.Tian,X.F.Yu,ACS
Appl.Mater.Interfaces, 2018,10,19398-19407. multifunctional nanoparticle can realize that diagnosis and treatment are integrated excellent
Gesture is that simple ZIF-8 cannot achieve.Nowadays there are no be based on Si-GdNPs, photosensitizer and the integrated metal of ZIF-8
Organic framework materials.It is generated under near infrared light in view of Si-GdNPs excellent fluorescence/magnetic resonance imaging performance and Ce6 single
ZIF-8, Si-Gd NPs and Ce6 are combined and are developed a kind of simple method for closing by line state oxygen performance use for cancer treatment
At, it can be achieved that diagnosis and treatment are integrated, the multi-function metal organic frame nanoparticle that has a targeting is extremely urgent.
Summary of the invention
Present invention aims at existing insufficient in view of the above technology and problem, provide one kind mix gadolinium silicon nano/
The preparation method of the multi-functional diagnosis and treatment integration metal organic frame nano material of photosensitizer Ce6 self assembly.With 2-methylimidazole
For organic ligand and Zn2+For metal ion, reaction system one kettle way is added in Si-Gd nanoparticle and Ce6 photosensitizer and is quickly closed
At metal organic frame nanoparticle.Prepared diagnosis and treatment integration metal organic frame nanoparticle is overexpressed folacin receptor
The identification of cancer cell has specificity well and selectivity；And preparation method is simple, and in the experiment made on the living of tumor-bearing mice, card
The nano material, which is illustrated, can realize fluorescence/magnetic resonance bimodal imaging guidance chemistry/light Dynamic Synthesis treatment, meanwhile,
There is good application prospect to the Selective recognition of target tumor and drug treatment in the targeted delivery of actual drug.
Technical solution of the present invention:
One kind mixing the multi-functional diagnosis and treatment integration metal organic frame nanometer of gadolinium silicon nano/Ce6 photosensitizer self assembly
The preparation method of material, using 2-methylimidazole as organic ligand and Zn2+For metal ion, gadolinium silicon (Si-Gd) nanoparticle will be mixed
The multi-functional diagnosis and treatment integration metal organic frame nanoparticle of the quick one pot process of reaction system is added with Ce6 photosensitizer, bears
After carrying drug, in its surface modification pH responsiveness PDMAEMA linear polymer, then in surface modification MaL-PEG-FA, including such as
Lower step:
1) preparation for mixing gadolinium silicon nano, by trisodium citrate, diethylenetriamine pentaacetic acid and GdCl3.H2O is dissolved in
In ionized water, argon gas protection is lower to stir 10-20min, and 3- aminopropyl triethoxysilane (APTES) is added and continues to be vigorously stirred
Reactant is transferred in reaction kettle and is put into 180-200 DEG C of baking oven by 20-30min, obtains mixing gadolinium silicon nano after 2-3h；
2) purifying for mixing gadolinium silicon nano is down to room temperature to above-mentioned reaction product, is added to mixing in gadolinium silicon nano
Product after dilution is transferred to bag filter dialysed overnight by dilute hydrochloric acid, and what is purified mixes gadolinium silicon nano (Si-GdNPs)
Solution；
3) the gadolinium silicon nano of mixing of purifying is diluted with deionized water, the polyvinylpyrrolidone-of 25mg/mL is added
K30 (PVP) reacts 12-24h at room temperature, and centrifugal concentrating, PVP modification is made mixes gadolinium silicon nano (Si-Gd@PVP)；
4) the Si-Gd@PVP solution being prepared is added to ZnNO3In methanol solution, then by 2-methylimidazole solution and
Ce6 solution is added in above-mentioned reaction mixture, and magnetic force is vigorously stirred 60-90min, and centrifugation is cleaned with first alcohol and water and mixed
The double fluorescent nano particles (FZIF-8) of gadolinium silicon nano/Ce6 doping metal organic frame；
5) absorption in doxorubicin hydrochloride (DOX) solution is added in the FZIF-8 nanoparticle of preparation completely, to clean three times, obtain
There is the fluorescence metal organic frame nanoparticle (FZIF-8/DOX) of DOX to load；
6) polymethylacrylic acid prepared in deionized water by the FZIF-8/DOX nanoparticle dispersion of preparation, is added
Dimethylaminoethyl linear polymer (PDMAEMA), stirs 12-24h under room temperature, is cleaned with deionized water and obtained three times
The fluorescence metal organic frame nano material (FZIF-8/DOX-PD) of PDMAEMA modification；
7) in deionized water by the FZIF-8/DOX-PD nanoparticle dispersion of preparation, MaL-PEG-FA solution is added, uses
It is pH=8.5 that sodium hydroxide, which adjusts reaction system, and magnetic agitation reacts 8-12h, cleaned three times with deionized water, obtain MaL-
Double fluorescence diagnosis and treatment integration metal organic frame nano materials (FZIF-8/DOX-PD-FA) of PEG-FA modification.
Step 1) the trisodium citrate, diethylenetriamine pentaacetic acid, GdCl3.H2O, 3- aminopropyl triethoxysilane dosage
Than are as follows: 0.4-0.42g:0.3-0.32g:0.2-0.22g:2-2.2mL.
Step 2) is described to mix gadolinium silicon nano solution and hydrochloric acid volume ratio are as follows: 8mL:6-7mL, the concentration of the hydrochloric acid
For 1mol/L.
Gadolinium silicon nano solution, polyvinylpyrrolidone-k30 (PVP) volume ratio are mixed in the step 3) purifying are as follows:
10-12mL:4-6mL.
Step 4) the ZnNO3Solution, 2-methylimidazole solution, Si-Gd@PVP solution, Ce6 solution volume ratio are as follows:
30-31mL:30mL:0.5-6mL:0.2-3mL the ZnNO3Solution concentration is 14.6mg/mL, 2-methylimidazole solution concentration
For 32.4mg/mL.
Step 5) is described mix gadolinium silicon nano/Ce6 doping metal organic frame fluorescent nano particles (FZIF-8),
DOX solution proportion are as follows: the concentration of 2mg:5-10mL, the DOX are 0.2mg/mL.
Step 6) is described to load the double fluorescence metal organic frame nanoparticles (FZIF-8/DOX) for having DOX and poly- methyl-prop
The ratio of olefin(e) acid dimethylaminoethyl linear polymer (PDMAEMA) is 50mg:5-10mg.
The ratio of step 7) the FZIF-8/DOX-PD nanoparticle and MaL-PEG-FA are as follows: 50mg:6-10mg.
The advantages of the present invention:
1) gadolinium silicon nano is mixed as a kind of novel nano-material, while having both the excellent spy of fluorescence and high-specific surface area
Property, it is excellent glimmering applied to prepared nano particle can be made to have in the preparation process of metal organic frame nanoparticle
Light and magnetic resonance properties；
2) during preparing metal organic frame nanoparticle, in addition to mixing gadolinium silicon nano while being also doped with
Ce6 photosensitizer, so that metal organic frame nanoparticle has Two Colour Fluorescence；
3) metal organic frame nanoparticle prepared by has meso-hole structure can be with carrying medicament and Ce6
Near infrared light shines lower generation singlet oxygen, so that bimodal treatment may be implemented in the nanoparticle；
4) this it is nanoparticle surface modified have PDMAEMA that can prevent drug leakage, furthermore be modified with MaL-PEG-FA,
Targeted imaging and targeted therapy are also achieved while enhancing biocompatibility.
Detailed description of the invention
Fig. 1 is the saturating of the diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA) that load has DOX
Penetrate electron microscope.
Fig. 2 is that diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA) (40 μ g/mL, 4h) is right
The laser capture microdissection of MCF-7 mammary tumor cells specific identification is total to focused view.(FZIF-8/DOX be no targeted nano-particle and
A549 be folacin receptor feminine gender expression cell as a control group, blue is Si-GdNPs, and yellow is Ce6, and red is DOX).
Fig. 3 be FZIF-8/DOX-PD-FA+NIR to MCF-7 mammary gland solid tumor mouse therapeutic effect figure (PBS,
DOX, FZIF-8-PD-FA+NIR, FZIF-8/DOX-PD-FA are as a control group), it shows in figure: FZIF-8/DOX-PD-FA+
NIR has best therapeutic effect to target MCF-7 mammary gland solid tumor.
Specific embodiment
Embodiment 1:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method specifically comprises the following steps:
1) preparation for mixing gadolinium silicon nano, by 0.4g trisodium citrate, 0.3g diethylenetriamine pentaacetic acid with
0.2gGdCl3.H2O is dissolved in 8mL deionized water, is vigorously stirred 20min under argon gas protection, three second of 2mL 3- aminopropyl is added
Oxysilane (APTES) continues to be vigorously stirred 30min and be put into reaction kettle to be reacted, and 200 DEG C, obtains mixing gadolinium silicon nanometer after 3h
Particle；
2) purifying for mixing gadolinium silicon nano mixes to 8mL and dilute salt that 6mL concentration is 1mol/L is added in gadolinium silicon nano
Acid, dialysed overnight, what is purified mixes gadolinium silicon nano (Si-GdNPs) solution；
3) 10mL of purifying is mixed gadolinium silicon nano to be add to deionized water, the polyethylene of 4mL (25mg/mL) is added
Pyrrolidones-k30 (PVP) reacts for 24 hours, centrifugal concentrating at room temperature, and PVP modification is made mixes gadolinium silicon nano (Si-Gd@
PVP)；
4) the 2mL Si-Gd@PVP solution being prepared is added to 30mLZnNO3In methanol solution, then by 30mL2- first
Base imidazole solution and 0.2mLCe6 solution are added in above-mentioned reaction mixture, and magnetic force is vigorously stirred 60min, and methanol is used in centrifugation
It cleans to obtain with water and mixes gadolinium silicon nano/Ce6 self assembly metal organic frame fluorescent nano particles (FZIF-8)；
5) 5mL doxorubicin hydrochloride (DOX) absorption is added completely in the 2mgFZIF-8 nanoparticle of preparation, cleaning three times, obtains
There is the fluorescence metal organic frame nanoparticle (FZIF-8/DOX) of DOX to load；
6) the poly- first of the 5mg prepared in deionized water by the 50mgFZIF-8 DOX nanoparticle dispersion of preparation, is added
Base dimethylaminoethyl acrylate linear polymer (PDMAEMA), stirs for 24 hours under room temperature, is cleaned three times with deionized water
Obtain the multi-functional diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD) of PDMAEMA modification；
7) MaL-PEG-FA in deionized water by the 50mg FZIF-8/DOX-PD nanoparticle dispersion of preparation, is added
(6mg), adjusting reaction system with sodium hydroxide is pH=8.5, and magnetic agitation reacts 12h, cleaned three times, obtained with deionized water
Double fluorescence metal organic frame nano materials (FZIF-8/DOX-PD-FA) of PEG-FA modification.
Fig. 1 is the saturating of the diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA) that load has DOX
Penetrate electron microscope.Show in figure: particle size is about 80nm.
Fig. 2 is that diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA) (40 μ g/mL, 4h) is right
The laser capture microdissection of MCF-7 mammary tumor cells specific identification is total to focused view.(FZIF-8/DOX is no targeted nano-particle, A549
Be folacin receptor feminine gender expression tumour cell as a control group, blue is Si-GdNPs, and yellow is Ce6, and red is DOX).Figure
Middle display: prepared FZIF-8/DOX-PD-FA, which is overexpressed MCF-7 breast cancer cell to target folacin receptor, specific recognition
Targeting, compared to FZIF-8/DOX and A549 cell, FZIF-8/DOX-PD-FA enters the nanoparticle of MCF-7 cell interior
It is sub more.
Fig. 3 be FZIF-8/DOX-PD-FA+NIR to MCF-7 mammary gland solid tumor mouse therapeutic effect figure (PBS,
DOX, FZIF-8-PD-FA+NIR, FZIF-8/DOX-PD-FA are as a control group), it shows in figure: FZIF-8/DOX-PD-FA+
NIR has best therapeutic effect to target MCF-7 mammary gland solid tumor.
Embodiment 2:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) takes 0.42g trisodium citrate to be added to
In 8mL deionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
The preparation method characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 of material are similar.
Embodiment 3:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) takes 0.32g diethylenetriamine pentaacetic acid to add
Enter in 8mL deionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 4:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 2) mixes the purifying of gadolinium silicon nano, will
8mL mixes gadolinium silicon nano and 7mL (1mol/L) dilute hydrochloric acid is added.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 5:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 3) is received to the gadolinium silicon of mixing of 10ml after purification
Polyvinylpyrrolidone-the k30 of 6mL (25mg/ml) is added in rice corpuscles solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 6:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: 2mL Ce6 solution is added reaction and mixed by step 4)
It closes in solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 7:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: 3mL Ce6 solution is added reaction and mixed by step 4)
It closes in solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 8:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: 4mL Ce6 solution is added reaction and mixed by step 4)
It closes in solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 9:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 5) 2mg FZIF-8 nanoparticle is added
6mL doxorubicin hydrochloride (DOX) absorption is complete.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 10:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 5) 2mg FZIF-8 nanoparticle is added
8mL doxorubicin hydrochloride (DOX) absorption is complete.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 11:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 6) 50mg FZIF-8/DOX nanoparticle
In deionized water, the 8mg polymethylacrylic acid dimethylaminoethyl linear polymer (PDMAEMA) prepared is added in dispersion.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 12:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 6) 50mg FZIF-8/DOX nanoparticle
In deionized water, the 10mg polymethylacrylic acid dimethylaminoethyl linear polymer (PDMAEMA) prepared is added in dispersion.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 13:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 7) is by the 50mgFZIF-8/DOX- of preparation
PD nanoparticle disperses in deionized water, to be added MaL-PEG-FA (8mg).
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 14:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 7) is by the 50mgFZIF-8/DOX- of preparation
PD nanoparticle disperses in deionized water, to be added MaL-PEG-FA (10mg).
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 15:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: going for 8mL is added in 2.2mLAPTES by step 1)
In ionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 16:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) is by 0.22mL GdCl3.H2O is added
In the deionized water of 8mL.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 17:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 3) is received to the gadolinium silicon of mixing of 12ml after purification
Polyvinylpyrrolidone-the k30 of 6mL (25mg/ml) is added in rice corpuscles solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 18:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 3) is received to the gadolinium silicon of mixing of 12ml after purification
Polyvinylpyrrolidone-the k30 of 4mL (25mg/ml) is added in rice corpuscles solution.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar
Embodiment 19:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) takes 0.41g trisodium citrate to be added to
In 8mL deionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 20:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) takes 0.31g diethylenetriamine pentaacetic acid to add
Enter in 8mL deionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 21:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: step 1) is by 0.21mL GdCl3.H2O is added
In the deionized water of 8mL.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Embodiment 22:
A kind of gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nano material of mixing
Preparation method, synthesis step is substantially the same manner as Example 1, the difference is that: going for 8mL is added in 2.1mLAPTES by step 1)
In ionized water.
Gadolinium silicon nano/photosensitizer Ce6 self assembly diagnosis and treatment integration metal organic frame nanometer material is mixed in final preparation
Material characterization and FZIF-8/DOX-PD-FA application result and embodiment 1 are similar.
Claims (8)
1. one kind mixes gadolinium silicon nano/Ce6 photosensitizer self-assembling multifunctional diagnosis and treatment integration metal organic frame nano material
Preparation method, using 2-methylimidazole as organic ligand and Zn2+For metal ion, gadolinium silicon (Si-Gd) nanoparticle and Ce6 will be mixed
The multi-functional diagnosis and treatment integration metal organic frame nanoparticle of reaction system one kettle way rapid synthesis is added in photosensitizer, loads medicine
After object, in its surface modification pH responsiveness PDMAEMA linear polymer, MaL-PEG-FA is further modified, including walk as follows
It is rapid:
1) preparation for mixing gadolinium silicon nano, by trisodium citrate, diethylenetriamine pentaacetic acid and GdCl3.H2O is dissolved in deionization
In water, argon gas protection is lower to stir 10-20min, and 3- aminopropyl triethoxysilane (APTES) is added and continues to stir 20-30min,
Reactant is transferred in autoclave and is put into baking oven, 180-200 DEG C, obtains mixing gadolinium silicon nano after 2-3h；
2) purifying for mixing gadolinium silicon nano is down to room temperature to above-mentioned reaction product, is added to mixing in gadolinium silicon nano solution
Product after dilution is transferred to bag filter by dilute hydrochloric acid, and dialysed overnight, what is purified mixes gadolinium silicon nano (Si-GdNPs)
Solution；
3) the gadolinium silicon nano of mixing of purifying is diluted with deionized water, the polyvinylpyrrolidone-k30 of 25mg/mL is added
(PVP), 12-24h is reacted at room temperature, and centrifugal concentrating, PVP modification is made mixes gadolinium silicon nano (Si-Gd@PVP)；
4) the Si-Gd@PVP solution being prepared is added to ZnNO3In methanol solution, then 2-methylimidazole solution and Ce6 is molten
Liquid is added in above-mentioned reaction mixture, and magnetic force is vigorously stirred 60-90min, centrifugation, cleans to obtain with first alcohol and water and mixes gadolinium silicon and receive
Rice corpuscles/Ce6 doping metal organic frame fluorescent nano particles (FZIF-8)；
5) the FZIF-8 nanoparticle of preparation is added in doxorubicin hydrochloride (DOX) solution and is adsorbed completely, cleaning is loaded
There is the fluorescence metal organic frame nanoparticle (FZIF-8/DOX) of DOX；
6) the polymethylacrylic acid diformazan prepared in deionized water by the FZIF-8/DOX nanoparticle dispersion of preparation, is added
Amino ethyl ester linear polymer (PDMAEMA), stirs 12-24h under room temperature, cleans to obtain PDMAEMA with deionized water and repair
The fluorescence metal organic frame nano material (FZIF-8/DOX-PD) of decorations；
7) in deionized water by the FZIF-8/DOX-PD nanoparticle dispersion of preparation, MaL-PEG-FA solution is added, uses hydrogen-oxygen
Changing sodium to adjust reaction system is pH=8.5, and magnetic agitation is reacted 8-12h, cleaned with deionized water, and MaL-PEG-FA modification is obtained
Diagnosis and treatment integration metal organic frame nano material (FZIF-8/DOX-PD-FA).
2. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: the step 1) trisodium citrate, diethylenetriamine pentaacetic acid,
GdCl3.H2O, 3- aminopropyl triethoxysilane amount ratio are as follows: 0.4-0.42g:0.3-0.32g:0.2-0.22g:2-2.2mL.
3. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: step 2) is described to mix gadolinium silicon nano solution and dilute hydrochloric acid volume
Ratio are as follows: 8mL:6-7mL, the concentration of hydrochloric acid are 1mol/L.
4. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: gadolinium silicon nano solution, polyethylene are mixed in the step 3) purifying
Pyrrolidones-k30 volume ratio are as follows: 10-12mL:4-6mL.
5. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: the step 4) ZnNO3Solution, 2-methylimidazole solution, Si-Gd@
The volume ratio of PVP solution, Ce6 solution are as follows: 30-31mL:30mL:0.5-6mL:0.2-3mL, the ZnNO3Solution concentration is
14.6mg/mL, 2-methylimidazole solution concentration are 32.4mg/mL.
6. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: step 5) gadolinium silicon nano/Ce6 doping metal of mixing has
Machine frame double fluorescent nano particles (FZIF-8), DOX solution proportion are as follows: the concentration of 2mg:5-10mL, the DOX are 0.2mg/
mL。
7. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: step 6) is described to load the fluorescence metal organic frame nanometer for having DOX
The ratio of particle (FZIF-8/DOX) and polymethylacrylic acid dimethylaminoethyl linear polymer (PDMAEMA) is 50mg:5-
10mg。
8. mixing the multi-functional diagnosis and treatment integration metal of gadolinium silicon nano/Ce6 photosensitizer self assembly according to claim 1 has
The preparation method of machine frame nano material, it is characterised in that: step 7) the FZIF-8/DOX-PD nanoparticle and MaL-PEG-
The ratio of FA are as follows: 50mg:6-10mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910541710.8A CN110227157A (en) | 2019-06-21 | 2019-06-21 | Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910541710.8A CN110227157A (en) | 2019-06-21 | 2019-06-21 | Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110227157A true CN110227157A (en) | 2019-09-13 |
Family
ID=67857062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910541710.8A Pending CN110227157A (en) | 2019-06-21 | 2019-06-21 | Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110227157A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467491A (en) * | 2020-04-24 | 2020-07-31 | 东南大学 | Synthesis of platinum modified MOF2-Pt-FA as bidirectional enhanced photodynamic therapy medicine and application of platinum modified MOF2-Pt-FA in tumor therapy |
| CN112755183A (en) * | 2019-11-04 | 2021-05-07 | 华中科技大学 | Organic metal framework nano material, preparation and application thereof |
| CN117138055A (en) * | 2023-06-02 | 2023-12-01 | 中山大学附属第一医院 | Double-carrier doxorubicin drug-loaded nano material and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105271266A (en) * | 2015-10-21 | 2016-01-27 | 哈尔滨工程大学 | Preparation method of multifunctional mesoporous Gd-Si-Ce6 nanocomposite with core-shell structure |
| CN106362146A (en) * | 2016-08-10 | 2017-02-01 | 福州大学 | Preparation and application of ZIF-8@zinc phthalocyanine composite |
| CN106512023A (en) * | 2016-12-02 | 2017-03-22 | 武汉理工大学 | Preparation method of difunctional mesoporous silicon ball composite targeted drug delivery system |
| CN107596391A (en) * | 2017-11-09 | 2018-01-19 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of metal organic frame base nanometer diagnosis and treatment probe and products thereof and application |
| CN108619511A (en) * | 2018-04-20 | 2018-10-09 | 山东大学 | A kind of preparation method and application of the metal organic frame drug-loading system based on cytarabine small molecule prodrugs |
| CN108815523A (en) * | 2018-07-05 | 2018-11-16 | 中国人民解放军第二军医大学第二附属医院 | A kind of New Type of Mesoporous silicon ball is total to medicament-carried nano compound and preparation method thereof |
| CN109172587A (en) * | 2018-09-07 | 2019-01-11 | 上海大学 | A kind of metal organic frame-that pH responds double drug releases goes up the preparation method and application of conversion nano system |
| WO2019028250A1 (en) * | 2017-08-02 | 2019-02-07 | The University Of Chicago | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, rodiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| CN109512797A (en) * | 2018-12-21 | 2019-03-26 | 上海纳米技术及应用国家工程研究中心有限公司 | The preparation method of nano-medicament carrier and products thereof based on metal organic frame |
-
2019
- 2019-06-21 CN CN201910541710.8A patent/CN110227157A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105271266A (en) * | 2015-10-21 | 2016-01-27 | 哈尔滨工程大学 | Preparation method of multifunctional mesoporous Gd-Si-Ce6 nanocomposite with core-shell structure |
| CN106362146A (en) * | 2016-08-10 | 2017-02-01 | 福州大学 | Preparation and application of ZIF-8@zinc phthalocyanine composite |
| CN106512023A (en) * | 2016-12-02 | 2017-03-22 | 武汉理工大学 | Preparation method of difunctional mesoporous silicon ball composite targeted drug delivery system |
| WO2019028250A1 (en) * | 2017-08-02 | 2019-02-07 | The University Of Chicago | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, rodiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| CN107596391A (en) * | 2017-11-09 | 2018-01-19 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of metal organic frame base nanometer diagnosis and treatment probe and products thereof and application |
| CN108619511A (en) * | 2018-04-20 | 2018-10-09 | 山东大学 | A kind of preparation method and application of the metal organic frame drug-loading system based on cytarabine small molecule prodrugs |
| CN108815523A (en) * | 2018-07-05 | 2018-11-16 | 中国人民解放军第二军医大学第二附属医院 | A kind of New Type of Mesoporous silicon ball is total to medicament-carried nano compound and preparation method thereof |
| CN109172587A (en) * | 2018-09-07 | 2019-01-11 | 上海大学 | A kind of metal organic frame-that pH responds double drug releases goes up the preparation method and application of conversion nano system |
| CN109512797A (en) * | 2018-12-21 | 2019-03-26 | 上海纳米技术及应用国家工程研究中心有限公司 | The preparation method of nano-medicament carrier and products thereof based on metal organic frame |
Non-Patent Citations (5)
| Title |
|---|
| JIAO-TONG SUN ET AL: ""Fabrication of PDEAEMA-Coated Mesoporous Silica Nanoparticles and pH-Responsive Controlled Release"", 《J. PHYS. CHEM. C》 * |
| SI LI ET AL: ""One-pot hydrothermal preparation of gadolinium-doped silicon nanoparticles as a dual-modal probe for multicolor fluorescence and magnetic resonance imaging"", 《J. MATER. CHEM. B》 * |
| YA-TING QIN ET AL: ""pH-Responsive Polymer-Stabilized ZIF‑8 Nanocomposites for Fluorescence and Magnetic Resonance Dual-Modal Imaging-Guided Chemo-/Photodynamic Combinational Cancer Therapy"", 《ACS APPL. MATER. INTERFACES》 * |
| ZHONGXI XIE ET AL: ""O2‑Loaded pH-Responsive Multifunctional Nanodrug Carrier for Overcoming Hypoxia and Highly Efficient Chemo-Photodynamic", 《CHEM. MATER》 * |
| 郑晓鹏 等: ""荧光上转换纳米材料在光动力学治疗癌症中的应用"", 《中国肿瘤临床》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112755183A (en) * | 2019-11-04 | 2021-05-07 | 华中科技大学 | Organic metal framework nano material, preparation and application thereof |
| CN112755183B (en) * | 2019-11-04 | 2021-12-17 | 华中科技大学 | Organic metal framework nano material, preparation and application thereof |
| CN111467491A (en) * | 2020-04-24 | 2020-07-31 | 东南大学 | Synthesis of platinum modified MOF2-Pt-FA as bidirectional enhanced photodynamic therapy medicine and application of platinum modified MOF2-Pt-FA in tumor therapy |
| CN117138055A (en) * | 2023-06-02 | 2023-12-01 | 中山大学附属第一医院 | Double-carrier doxorubicin drug-loaded nano material and preparation method thereof |
| CN117138055B (en) * | 2023-06-02 | 2024-04-16 | 中山大学附属第一医院 | Double-carrier doxorubicin drug-loaded nano material and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110227157A (en) | Mix gadolinium silicon nano/photosensitizer self assembly metal organic frame nano material preparation method | |
| CN106267204B (en) | A kind of composite material and preparation method and application of black phosphorus nanometer sheet-antitumoral compounds | |
| Bagheri et al. | Controlled direct growth of polymer shell on upconversion nanoparticle surface via visible light regulated polymerization | |
| CN105903016B (en) | A kind of preparation method of the nuclear shell structure drug carrier of the near infrared light excitation light-operated drug release of supermolecule valve | |
| Cao et al. | Pt@ polydopamine nanoparticles as nanozymes for enhanced photodynamic and photothermal therapy | |
| Hong et al. | Intense red-emitting upconversion nanophosphors (800 nm-driven) with a core/double-shell structure for dual-modal upconversion luminescence and magnetic resonance in vivo imaging applications | |
| CN107412195A (en) | A kind of antineoplastic drug carrier material of pH responses and its preparation and application | |
| CN105214095B (en) | The multi-functional nanometer material and preparation method of metal organic frame meso-hole structure | |
| CN102078617B (en) | Method for synthesizing mesoporous silica-based nanocomposite embedded with gold nanorods | |
| Wen et al. | In situ formation of homogeneous tellurium nanodots in paclitaxel-loaded MgAl layered double hydroxide gated mesoporous silica nanoparticles for synergistic chemo/PDT/PTT trimode combinatorial therapy | |
| CN102782573A (en) | Rare earth-doped up-conversion nanoparticles for therapeutic and diagnostic applications | |
| Chen et al. | Protonated 2D carbon nitride sensitized with Ce6 as a smart metal-free nanoplatform for boosted acute multimodal photo-sono tumor inactivation and long-term cancer immunotherapy | |
| Liu et al. | Smart “on-off” responsive drug delivery nanosystems for potential imaging diagnosis and targeted tumor therapy | |
| CN110819339B (en) | Cu-amino acid composite up-conversion nano material and preparation method thereof | |
| Liu et al. | Dual-path modulation of hydrogen peroxide to ameliorate hypoxia for enhancing photodynamic/starvation synergistic therapy | |
| CN108310388A (en) | The preparation method and its usage of the fluorescence mesoporous silica nano particle of disulfide bond functionalization | |
| CN105999283A (en) | Preparation method for adriamycin-loaded polyethyleneimine-hyaluronic acid-modified hectorite-coated gold nanoparticles | |
| Pu et al. | Green synthesis of highly dispersed ytterbium and thulium co-doped sodium yttrium fluoride microphosphors for in situ light upconversion from near-infrared to blue in animals | |
| Sun et al. | A facile approach to carbon dots‐mesoporous silica nanohybrids and their applications for multicolor and two‐photon imaging guided chemo‐/photothermal synergistic oncotherapy | |
| Hou et al. | Full-active Cu2O/drug core/shell nanoparticles based on “grafting from” drug coordination polymerization combined with PD-1 blockade for efficient cancer therapy | |
| CN110169958A (en) | A kind of preparation method of the multi-functional mesoporous silicon oxide composite nano materials based on Fluorescent silicon nanoparticle | |
| CN106581683B (en) | A kind of polyethyleneglycol modified metal organic nano material and preparation method thereof, application | |
| He et al. | Intelligent manganese dioxide nanocomposites induce tumor immunogenic cell death and remould tumor microenvironment | |
| Liu et al. | Dual-responsive nanomotors for deep tumor penetration and subcellular arrangement | |
| CN104147608B (en) | Lithium amide soapstone nano particles modified by polyethylene glycol-folic acid as well as preparation and application of lithium amide soapstone nano particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190913 |
|
| WD01 | Invention patent application deemed withdrawn after publication |